RECRUITING

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity \[Pediatric RISE\]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes. Participants will be randomized to receive one of the following for 6-months: * Usual supportive care alone or * Usual supportive care plus Pediatric RISE

Official Title

A Randomized Phase II Trial Evaluation of the Addition of the Resource Intervention to Support Equity (RISE) to Usual Supportive Care for Children With Newly Diagnosed High-Risk Neuroblastoma

Quick Facts

Study Start:2025-04-30
Study Completion:2029-06-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06831552

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 17 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * Patient newly diagnosed with high-risk neuroblastoma
  2. * Patient has established care at study site and initiated cancer-directed therapy
  3. * Patient has not yet initiated Induction Cycle 3
  4. * Patient aged 0-17 years at the time of consent
  5. * Parent/guardian screened positive for self-reported low-income (\<200% Federal Poverty) \*
  6. * Family primary residence in MA, PA, IL, CA, WA, CT, GA, WI and OH
  7. * Both patients co-enrolled on ANBL2131 or those receiving standard of care therapy at their center are eligible to participate
  8. * Patients of all languages are eligible to participate
  1. * Foreign national family receiving care as an Embassy-pay patient.
  2. * Child or household member receiving SSI

Contacts and Locations

Study Contact

Kira Bona, MD, MPH
CONTACT
617-632-4688
Kira_Bona@dfci.harvard.edu

Principal Investigator

Kira Bona, MD, MPH
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Dana-Farber Cancer Institute
Boston, Massachusetts, 03079
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Kira Bona, MD, MPH, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-30
Study Completion Date2029-06-01

Study Record Updates

Study Start Date2025-04-30
Study Completion Date2029-06-01

Terms related to this study

Keywords Provided by Researchers

  • Neuroblastoma
  • High-risk Neuroblastoma

Additional Relevant MeSH Terms

  • Neuroblastoma
  • High-risk Neuroblastoma